China’s Junshi Biosciences (HKEX: 1877) yesterday revealed that its wholly-owned subsidiary TopAlliance Bioscience has entered into a distribution and marketing partnership with Danish dermatology specialist LEO Pharma for toripalimab in Europe.
This collaboration aims to promote the accessibility of toripalimab, which is marketed in some countries as Loqtorzi, in Europe, offering high-quality, innovative treatments to patients across up to 32 European countries.
Toripalimab, independently developed by Junshi Biosciences, is a monoclonal antibody targeting PD-1 for the treatment of multiple malignant tumors.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze